FOR IMMEDIATE RELEASE
Premier healthcare alliance
Suppliers participating in comparative effectiveness research program to determine safest, most efficient care
CHARLOTTE, N.C. (February 20, 2012) – Baxter International Inc., Deltex Medical and Nihon Kohden America Inc. have been selected to participate in the second phase of a voluntary program evaluating products and clinical interventions in real-world settings at Premier healthcare alliance hospitals.
Premier's QUEST® Comparative Effectiveness & Innovation Program (QCEIP) generates objective results to inform providers and patients about safe, cost-effective treatments for certain clinical conditions. It also helps the healthcare community better understand patient outcomes associated with the use of certain products.
"Testing products and clinical interventions in real-word settings is essential to ensure that safe, reliable and cost-effective care is delivered to every patient," said Bill Zeruld, vice president of Premier Research Services. "In collaborating with these suppliers and Premier alliance hospitals, we can accelerate patient access to the most innovative and efficient products and technologies."
All suppliers nationwide are eligible to join QCEIP, regardless of whether the company has a supply contract with Premier. Baxter, Lantheus Medical Imaging Inc. and Siemens Healthcare Diagnostics participated in the first phase of QCEIP. Results from these studies are pending peer review and have each been selected for presentation at Premier's annual Breakthroughs Conference and Exhibition in Nashville, Tenn.
Supplier applications are reviewed by a multidisciplinary team consisting of hospital experts from Premier's QUEST: High Performing Hospitals collaborative, Premier's Center for Evidence-Based Pharmacy Practice and Premier Research Services.
QCEIP consists of the following:
- Conducting a study that will correlate health outcomes to product performance using Premier's secondary data sources;
- Creating an abstract for publication based on the results of the secondary data analysis; and
- After clearing the peer review process, using a variety of communications channels to inform the Premier alliance and broader healthcare community of the study results.
The program leverages Premier Research Services' expertise and data from the nation's most comprehensive repository of clinical, financial and outcomes information to test, validate and substantiate the concepts submitted by the suppliers. Premier Research Services and Premier data have been featured in more than 200 peer-reviewed publications.
QUEST is a voluntary collaborative consisting of 293 hospitals nationwide that share data and best practices, while identifying and implementing opportunities for improvement to achieve top performance levels. In just three years, the QUEST charter member hospitals prevented an estimated 24,820 deaths and reduced healthcare spending by nearly $4.5 billion.
Baxter International Inc.
The primary objective of this study is to compare the cost savings as well as product effectiveness of the FDA cleared silicate substituted calcium phosphate, ACTIFUSE [Bone Graft Substitute], to rh-BMP in cases involving posterolateral spinal fusion.
"Advancing patient care is paramount to Baxter," said Ron Lloyd, general manager of the U.S. region of Baxter's BioScience business. "Participating in Premier's innovative research initiative is an important way to provide the healthcare community with evidence-based information that helps answer important questions around treatment effectiveness, health outcomes and cost-effectiveness."
The primary objective of this study is to compare the safety and efficiency of the esophageal Doppler monitoring system CardioQ versus current standard clinical practices for fluid management during surgery.
Ewan Phillips, Deltex Medical's CEO, commented, "Our CardioQ-EDM esophageal Doppler monitor has been shown in numerous trials to deliver better care and better health for patients undergoing major and high risk surgery through significant reductions in complications after surgery; as a result surgical lengths of stay are reduced by two to three days generating substantial cost savings. We are excited about being selected for QCEIP and expect to be able to demonstrate that our technology will improve outcomes and reduce costs in the real-world environment of some of America's leading hospitals."
Nihon Kohden America Inc.
The primary objective of this study is to compare resource utilization and lengths of stay when the Prefense Early Detection & Notification System is used versus without. Prefense provides continuous vital sign monitoring – also known as "defensive monitoring" – to be performed throughout the hospital, even in areas where no patient monitoring traditionally occurs.
Mike Dashefsky, vice president, Nihon Kohden America, said, "Nihon Kohden is excited to participate in the QCEIP program and contribute directly to Premier's efforts to transform healthcare. The Prefense Early Detection & Notification System closes the gap between the time when the patient's condition starts to deteriorate and a clinician is alerted, enabling quicker interventions at the point of care."
About the Premier healthcare alliance, Malcolm Baldrige National Quality Award recipient
Premier is a performance improvement alliance of more than 2,600 U.S. hospitals and 86,000-plus other sites using the power of collaboration and technology to lead the transformation to coordinated, high-quality, cost-effective care. Owned by hospitals, health systems and other providers, Premier operates a leading healthcare purchasing network with more than $4 billion in annual savings. Premier also maintains the nation's largest clinical, financial and outcomes database with information on 1 in 4 patient discharges. A world leader in delivering measurable improvements in care, Premier works with the Centers for Medicare & Medicaid Services. Headquartered in Charlotte, N.C., Premier also has an office in Washington. https://www.premierinc.com. Stay connected on Facebook, Twitter and YouTube.